Do I still need to take dasatinib after a bone marrow transplant?

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) is a malignant disease with poor prognosis, especially in children, and is more difficult to treat. Although current studies have shown that chemotherapy regimens containing imatinib can improve early event-free survival, allogeneic hematopoietic stem cell transplantation is still regarded as the main curative treatment. In this context, dasatinib, as a new type of ABL tyrosine kinase inhibitor, has gradually attracted attention.

The main indication of dasatinib is relapsed or refractory diseasePh+ ALL or chronic myelogenous leukemia (CML), and clinical studies have shown that it has significant efficacy. Especially for Ph+ ALL, in order to prevent disease recurrence after bone marrow transplantation, prophylactic treatment with dasatinib has become a potential strategy. Relevant studies have pointed out that the patient's molecular remission state can last for up to 7 months after discontinuing dasatinib. This finding provides new ideas for promoting treatment effects.

Although prophylactic use of dasatinib is not currently common in clinical practice, increasing evidence supports its effectiveness in eradicating minimal residual disease and preventing relapse. In addition, dasatinib has a simple route of administration and is relatively safe, making it suitable for a wide range of patient populations. These properties make dasatinib one of the important drugs to consider for patients after bone marrow transplantation.

It should be noted that although preliminary research results are optimistic, research on the preventive application of dasatinib is still in the exploratory stage, and more large-scale clinical trials are needed in the future to verify its efficacy and safety. In practical applications, the use of dasatinib should be comprehensively considered based on the patient's specific situation and the doctor's recommendations.